Paying the Bills: A Shifting Paradigm
In China, innovative medicines have historically faced an enormous struggle to achieve reimbursement: to be included on a list of drugs for which the government will pay some of the cost. However, the market is changing dramatically: moving from a phase of disproportionately high out-of-pocket payments and a lack of supplemental payment instruments to innovative payments. To form a systematic and stable payment system is essential to guarantee the sustainable development of innovative drugs.
But are innovative payments simply about discounted price and healthcare loans? How can pharmaceutical companies reconsider market access and reimbursement strategies when launching innovative drugs? How can the industry players collaborate on providing new pricing and creative solutions to the market?